Search results
Annovis Bio (NYSE:ANVS) Price Target Lowered to $26.00 at Canaccord Genuity Group
ETF DAILY NEWS· 3 days agoAnnovis Bio (NYSE:ANVS – Free Report) had its price target trimmed by Canaccord Genuity Group from $36.00 to $26.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently ...
St. George ranks in Top 10 cleanest metro areas in American Lung Association report
KSL Salt Lake City· 6 days agoAs many as 131.2 million people in the U.S. live where the air quality gets failing grades due to...
Are you one of the millions about to have cataract surgery? Here’s what ophthalmologists say you...
San Francisco Chronicle· 4 days agoThe vast majority of patients have excellent outcomes with few complications. Close to 4 million cataract surgeries are performed in the U.S. every year. Over 90% of patients have 20/20 vision ...
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study - Addex Therapeutics (NASDAQ:ADXN)
Benzinga· 5 days agoAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $35.82 Average PT from Analysts
ETF DAILY NEWS· 4 days agoShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are currently covering the stock, Marketbeat.com ...
NeuroSense Announces First Quarter 2024 Business Update
WRBL Columbus· 2 days agoNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update. "We were honored to ...
A year out from legal medical marijuana, legislature makes final updates - The Advocate-Messenger
The Danville Advocate-Messenger· 2 days agoKentucky is a year closer to legalized medical marijuana, and the state legislature is making its...
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
AOL· 5 days agoJust a few short years after coming to market, the latest GLP-1 drugs are showing versatility in battling diseases related to diabetes and obesity, lifting the fortunes and expectations for ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoAeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously announced share consolidation (or reverse ...
Are you one of the millions about to have cataract surgery? Here’s what ophthalmologists say you...
Stamford Advocate· 4 days agoThe vast majority of patients have excellent outcomes with few complications. Close to 4 million cataract surgeries are performed in the U.S. every year. Over 90% of patients have 20/20 vision ...
